角膜新生血管治疗的研究进展  

Progress in the therapy of corneal neovascularization

作　　者：闫春晓 刘梦欣 靳琳 张立军 Yan Chunxiao;Liu Mengxin;Jin Lin;Zhang Lijun(The Third People′s Hospital of Dalian Affiliated to Dalian Medical University,Dalian Municipal Eye Hospital,Liaoning Provincial Key Laboratory of Cornea and Ocular Surface Diseases,Liaoning Provincial Optometry Technology Engineering Research Center,Dalian 116033,China)

机构地区：[1]大连医科大学附属大连市第三人民医院,大连市眼科医院,辽宁省角膜与眼表疾病研究重点实验室,辽宁省眼视光技术工程研究中心,大连116033

出　　处：《中华眼科杂志》2025年第4期310-315,共6页Chinese Journal of Ophthalmology

基　　金：国家自然科学基金面上项目(82171032);辽宁省应用基础研究计划(2022JH2/101300036)。

摘　　要：角膜新生血管(CNV)是一种严重致盲性眼表病理改变,发病原因复杂,视力损伤程度重,虽然使用抗炎和抗血管生成药物以及行角膜移植手术已被证实具有一定治疗效果,但仍存在众多瓶颈问题,致使出现多学科技术交叉治疗的新趋势。本文汇总最新研究进展,基于CNV新的机制研究结果,回顾和总结近年CNV治疗的新技术和新策略,旨在为CNV的高效精准治疗提供更多参考。Corneal neovascularization,a severe pathologic change of the ocular surface,is usually caused by complex pathogeneses,and leads to severe vision damage and eventually corneal blindness.The applications of anti-inflammatory and anti-angiogenic drugs as well as keratoplasty have proved to have certain therapeutic effects.However,there are still numerous barriers that have not yet been fully overcome,prompting a trend towards treatment with multidisciplinary techniques.In this review,we summarize the latest research progress and give an overview of the techniques and strategies for treatment of corneal neovascularization in recent years based on the new mechanistic findings,aiming to improve the therapeutic efficiency and precision.

关 键 词：角膜新生血管化 药物释放系统 基因治疗 干细胞移植 外泌体 角膜移植 

分 类 号：R772.2[医药卫生—眼科]